ABVC BioPharma
ABVC
ABVC BioPharma (ABVC) earnings history
Most recent quarter
- Fiscal period
- Q3 2023
- Period end
- Sep 30, 2023
- EPS actual
- −$0.82
- EPS estimate
- −$0.40
- EPS surprise
- −105.00%
- Revenue surprise
- −94.71%
- Revenue
- $15,884.00
- Revenue estimate
- $300,000.00
- Reported
- Nov 15, 2023
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2023 | Nov 15, 2023 | −$0.40 | −$0.82 | −105.00% | $15,884.00 | SEC |
| Q4 2022 | Mar 31, 2023 | −$1.50 | −$1.50 | +0.00% | $589,783.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$2.00 | −$1.10 | +45.00% | $42,269.00 | — |
| Q2 2022 | Aug 15, 2022 | −$1.25 | −$0.60 | +52.00% | $312,860.00 | — |
| Q1 2022 | May 16, 2022 | $0.00 | −$2.05 | +0.00% | $25,660.00 | — |
| Q2 2021 | Aug 12, 2021 | −$0.40 | −$0.80 | −100.00% | $31,441.00 | — |
Quarterly revenue
Frequently asked questions
When did ABVC BioPharma (ABVC) last report earnings?
ABVC BioPharma last reported on Nov 15, 2023, covering fiscal Q3 2023.
Did ABVC beat earnings estimates?
No. ABVC BioPharma reported EPS of −$0.82 for Q3 2023 against a −$0.40 estimate — a 105.00% miss.
How much revenue did ABVC report last quarter?
ABVC BioPharma reported $15,884.00 in revenue for Q3 2023, against a consensus estimate of $300,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.